Products
Anetumab Ravtansine Biosimilar Antibody-Drug Conjugate (Mesothelin) for Research
Pre-made Anetumab Ravtansine benchmark antibody (Whole mAb ADC, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
ImmunoGen, Inc. (Nasdaq: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.[2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-735-1mg | 1mg | |
| GMP-Bios-INN-735-10mg | 10mg | |
| GMP-Bios-INN-735-100mg | 100mg | |
| GMP-Bios-INN-735-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Anetumab Ravtansine Biosimilar, Whole Mab Adc, Anti-Msln Antibody: Anti-MPF/SMRP therapeutic antibody Drug Conjugate |
| INN Name | Anetumab Ravtansine |
| Target | MSLN |
| Format | Whole mAb ADC |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - lambda |
| VD LC | IgG1 - lambda |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | ImmunoGen Inc. (Cambridge MA USA) / Bayer HealthCare Pharmaceuticals (Leverkusen Germany) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | MorphoSys's HuCAL® phage library |
About target - MSLN
1. Protein Mesothelin
2. Gene MSLN
3. Organism Homo sapiens (Human)
Function
Membrane-anchored forms may play a role in cellular adhesion.
Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
